about
Sorafenib in advanced hepatocellular carcinomaStore-operated Ca2+ entry is remodelled and controls in vitro angiogenesis in endothelial progenitor cells isolated from tumoral patientsReceptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patientsEfficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThrombotic thrombocytopenic purpura and autoimmunity: a tale of shadows and suspects.Cisplatin, mitomycin-C, 5-fluorouracil and leucovorin combination chemotherapy (l-FCM) in locally advanced unresectable or metastatic gastric carcinoma: a phase-II study.Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexedAutoimmunity in thrombotic thrombocytopenic purpura.Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin.Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.Sunitinib in metastatic renal cell carcinoma patients with brain metastases.Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.Ocular involvement in acute thrombotic thrombocytopenic purpura.Intravenous prostacyclin (as epoprostenol) infusion in thrombotic thrombocytopenic purpura. Four case reports and review of the literature. Italian Cooperative Group for Thrombotic Thrombocytopenic Purpura.Vincristine sulfate for the treatment of thrombotic thrombocytopenic purpura refractory to plasma-exchange. The Italian Cooperative Group for TTP.Thrombotic thrombocytopenic purpura resistant to plasma-exchange: salvage treatment with high-dose IgG or vincristine. Italian Cooperative Group for TTP.Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP.Colon cancer in pregnancy: report of a case and review of the literature.Store-operated Ca2+ entry does not control proliferation in primary cultures of human metastatic renal cellular carcinoma.Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial.Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart reviewSorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trialImpact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countriesNatural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis surveyBone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy.Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis.The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?The role of the cell-cell interactions in cancer progression.Comparing comparators: a look at control arms in kidney cancer studies over the years.Sunitinib re-challenge in advanced renal-cell carcinoma.Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysisNew agents in the management of advanced mesothelioma.Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib.Concurrent intra-arterial carboplatin administration and radiation therapy for the treatment of advanced head and neck squamous cell carcinoma: short term resultsTolerability of first-line therapy for metastatic renal cell carcinoma.Sorafenib tosylate in advanced kidney cancer: past, present and future.Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma.
P50
Q27861075-A023E5A5-2DE7-4800-9B9B-D7C6136064EDQ28484028-E8450C0B-F5CA-4DD4-A16B-0CA0D681A00CQ28740575-E79B3F8A-8099-451B-9839-A34C0369C650Q29618031-FB98785D-CE6C-4ED9-A7D0-CE126D4BFE7BQ30667485-05CEA403-6762-4367-8B72-34FAFF2A9E85Q31687917-03545E98-A040-4B5B-9946-ED42AACE33BFQ33274781-8566F557-0346-4C0E-963D-362DD22893E8Q33369759-08D2D4F7-B13A-4E78-B8C4-F7BD75B7CDB2Q33375908-FCA8D317-6441-4EF0-925C-629173253F3BQ33385435-2D35FDE0-E4E6-447F-83B8-ADB6CC4B179CQ33391978-769473C9-27B6-45A1-8B4C-05C4403B882CQ33419797-FF5A1191-EF9C-4420-921C-CE46D836AA7AQ33423740-613FA887-6EAF-494C-89BF-9CD5EE974517Q33488829-870354FF-11DD-428D-9D35-A7E51154FE10Q33490325-8FA3E3B3-C405-4F5A-8AA7-18EE4A7BE05DQ33491529-83F4BAFB-7CEE-4530-B2A2-BDF160B85F9DQ33491568-ED29D951-035A-4FB9-976F-CAA0B5F0EEFEQ33500329-3FE099A2-F865-472C-AF93-BD1C001AF960Q33897909-1CC0D534-AF1D-4BA7-96F3-F0D80056F244Q33994049-DAF07A8C-53DB-415A-9C96-CF8CA38E923AQ34081620-51366EA9-13DA-4EBA-B0E6-04AE447F0258Q34657590-FA346B89-C7EB-4BB0-A418-D3EB707CE369Q34660431-ADA016BD-B5BE-4B24-B9AF-3A5041DDA1AAQ34806694-C19CAB84-7486-4ECE-AA96-D0B823B06466Q34982554-1F54DFF0-2E00-4ED1-BE1B-7AD13C9EB899Q35080143-A62B84D9-2E69-4003-B095-2006B2C4E5E1Q35083485-CD729861-E421-4B8D-BFF3-76EB2079786FQ35205445-AD5188AD-105A-4076-BA11-DA789559AC2BQ35241042-60C44708-DB28-475A-B001-3914B141E290Q35464515-4905A05E-7A4E-4E4F-B5D8-ECB288AF7F4EQ35531372-9D78852C-7B5A-4FD5-9C21-27A3C10564FAQ35677657-6F2C5918-C91B-4B43-9AD1-D53B0A7D5F01Q35678358-AC7503DC-1C8E-4FF8-B64E-F5E1E64B0F9FQ35927136-3E26453B-CA3F-422E-92E4-187238F440F9Q36179396-BB194BD8-06C9-4D52-BE61-47D6DDFA07F5Q37054905-648500ED-B69B-45D5-9F39-19F1CF76A855Q37357981-BEA37127-478D-4D67-9E86-912AEC3994FFQ37403087-1103B5E2-57B4-4EFB-B5A9-E96D5A9CEEBBQ37478886-E29D75D0-E93A-4211-B8D5-BB7EF0902058Q37612384-F476CA70-F5D7-4AAC-9B32-7218327B8C5C
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Camillo Porta
@ast
Camillo Porta
@en
Camillo Porta
@es
Camillo Porta
@nl
Camillo Porta
@sl
type
label
Camillo Porta
@ast
Camillo Porta
@en
Camillo Porta
@es
Camillo Porta
@nl
Camillo Porta
@sl
prefLabel
Camillo Porta
@ast
Camillo Porta
@en
Camillo Porta
@es
Camillo Porta
@nl
Camillo Porta
@sl
P106
P21
P2798
P31
P496
0000-0003-2412-1563